scholarly journals An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

2011 ◽  
Vol 27 (6) ◽  
pp. 2303-2311 ◽  
Author(s):  
J.-C. Galle ◽  
K. Claes ◽  
I. Kiss ◽  
C. G. Winearls ◽  
H. Herlitz ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Darbepoetin Alfa ◽  
Observational Cohort Study ◽  
Observational Cohort

scholarly journals Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252186
Author(s):  
Hayne Cho Park ◽  
AJin Cho ◽  
Do Hyoung Kim ◽  
Kyu-sang Yun ◽  
Juhee Kim ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Cohort Study ◽  
Kidney Disease ◽  
Adverse Events ◽  
Serum Creatinine ◽  
Observational Cohort Study ◽  
Prospective Observational Cohort Study ◽  
Renal Function Decline ◽  
Observational Cohort

Renamezin® is a modified capsule-type oral spherical adsorptive carbon which lowers indoxyl sulfate levels in patients with advanced chronic kidney disease (CKD). This 24-week prospective observational cohort study was performed to evaluate the effect of Renamezin® upon attenuation of renal function decline. A total of 1,149 adult patients with baseline serum creatinine 2.0–5.0 mg/dL were enrolled from 22 tertiary hospital in Korea from April 2016 to September 2018. Among them, a total of 686 patients completed the study and were included in the intention-to-treat analysis. A total of 1,061 patients were included in the safety analysis. The mean age was 63.5 years and male patients were predominant (63.6%). Most of the patients (76.8%) demonstrated high compliance with study drug (6g per day). After 24 week of treatment, serum creatinine was increased from 2.86±0.72 mg/dL to 3.06±1.15 mg/dL (p<0.001), but estimated glomerular filtration rate was not changed significantly during observation period (22.3±6.8 mL/min/1.73m2 to 22.1±9.1 mL/min/1.73m2, p = 0.243). Patients with age over 65 years old and those under good systolic blood pressure control <130 mmHg were most likely to get benefit from Renamezin® treatment to preserve renal function. A total of 98 (9.2%) patients out of 1,061 safety population experienced 134 adverse events, of which gastrointestinal disorders were the most common. There were no serious treatment-related adverse events. Renamezin® can be used safely to attenuate renal function decline in moderately advanced CKD patients.

Progression of chronic kidney disease and the risk of tuberculosis: an observational cohort study

2019 ◽  
Vol 23 (5) ◽  
pp. 555-562 ◽  
Author(s):  
P. J-Y. Cho ◽  
C-Y. Wu ◽  
J. Johnston ◽  
M-Y. Wu ◽  
C-C. Shu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Observational Cohort Study ◽  
Observational Cohort

scholarly journals Association between management of metabolic syndrome and progression of early-stage chronic kidney disease: an observational cohort study

Renal Failure ◽  
2014 ◽  
Vol 37 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Jui-Hsiang Lin ◽  
Hung-Chieh Wu ◽  
Wen-Hung Huang ◽  
Chien-Lu Lu ◽  
Mei-Hua Cheng ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Early Stage ◽  
Observational Cohort Study ◽  
Observational Cohort

scholarly journals Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study

2011 ◽  
Vol 12 (1) ◽  
Author(s):  
Alberto Martínez-Castelao ◽  
José L Górriz ◽  
José M Portolés ◽  
Fernando De Alvaro ◽  
Aleix Cases ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Chronic Kidney Disease Stage ◽  
Observational Cohort Study ◽  
Disease Stage ◽  
Stage 4 ◽  
Observational Cohort ◽  
Baseline Characteristics
Sign in / Sign up

Export Citation Format

Share Document